Management of Febrile Neutropenia – a German Prospective Hospital Cost Analysis in Lymphoproliferative Disorders, Non-Small Cell Lung Cancer, and Primary Breast Cancer
Authors:
- Angela Ihbe-HeffingerAIAngela Ihbe-Heffinger
- Bernadette J. PaessensBPBernadette J. Paessens
- Christoph von SchillingCSChristoph von Schilling
- Margarita ShlaenMSMargarita Shlaen
- Nina GottschalkNGNina Gottschalk
- Karin BergerKarin Berger
- Rudolf BernardRBRudolf Bernard
- Marion KiechleMKMarion Kiechle
- Christian PeschelCPChristian Peschel
- Volker R. JacobsVJVolker R. Jacobs
- 1 January 2011
- journal article
- editorial
- Published by S. Karger AG in Onkologie
- Vol. 34 (5) , 241-246
Abstract
Febrile neutropenia/leukopenia (FN/FL) is the most frequent dose-limiting toxicity of myelosuppressive chemotherapy, but German data on economic consequences are limited. A prospective, multicentre, longitudinal, observational study was carried out to evaluate the occurrence of FN/FL and its impact on health resource utilization and costs in non-small cell lung cancer (NSCLC), lymphoproliferative disorder (LPD), and primary breast cancer (PBC) patients. Costs are presented from a hospital perspective. A total of 325 consecutive patients (47% LPD, 37% NSCLC, 16% PBC; 46% women; 38% age = 65 years) with 68 FN/FL episodes were evaluated. FN/FL occurred in 22% of the LPD patients, 8% of the NSCLC patients, and 27% of the PBC patients. 55 FN/FL episodes were associated with at least 1 hospital stay (LPD n = 34, NSCLC n = 10, PBC n = 11). Mean (median) cost per FN/FL episode requiring hospital care amounted to € 3,950 (€ 2,355) and varied between € 4,808 (€ 3,056) for LPD, € 3,627 (€ 2,255) for NSCLC, and € 1,827 (€ 1,969) for PBC patients. 12 FN/FL episodes (LPD n = 9, NSCLC n = 3) accounted for 60% of the total expenses. Main cost drivers were hospitalization and drugs (60 and 19% of the total costs). FN/FL treatment has economic relevance for hospitals. Costs vary between tumour types, being significantly higher for LPD compared to PBC patients. The impact of clinical characteristics on asymmetrically distributed costs needs further evaluation.Keywords
This publication has 19 references indexed in Scilit:
- Retrospective cost analysis of management of febrile neutropenia in cancer patients in SpainCurrent Medical Research and Opinion, 2009
- Cost of neutropenic complications of chemotherapyAnnals of Oncology, 2007
- Evaluating the Total Costs of Chemotherapy-Induced Febrile Neutropenia: Results from a Pilot Study with Community Oncology Cancer PatientsThe Oncologist, 2007
- Economic Burden of Haematological Adverse Effects in Cancer PatientsClinical Drug Investigation, 2007
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsCancer, 2006
- Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide StudyJournal of Clinical Oncology, 2004
- Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community PracticesJournal of Clinical Oncology, 2003
- Antimicrobial therapy of unexplained fever in neutropenic patientsAnnals of Hematology, 2003
- Management of Fever in Patients with Cancer and Treatment-Induced NeutropeniaNew England Journal of Medicine, 1993
- Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute LeukemiaAnnals of Internal Medicine, 1966